I'm on semaglutide and my resting heart rate has gone up 5 bpm. Should I be worried?

A 2–4 bpm increase in resting heart rate is expected with GLP-1 receptor agonists, it is a direct pharmacological effect of GLP-1R activation on the sinoatrial node (the heart's natural pacemaker), and it was observed and tracked in the SELECT trial without any association with worse cardiovascular outcomes. An increase of 5 bpm is at the upper edge of typical but still within the range of this expected pharmacological effect.

The monitoring threshold for concern is: a persistent increase above 8–10 bpm over pre-treatment baseline that persists beyond six weeks, any new symptoms of palpitations or pounding heartbeat, or a resting heart rate that exceeds 90 bpm consistently. If your resting heart rate increase is precisely 5 bpm, you have no symptoms of palpitations or lightheadedness, and your heart rate is still below 80 bpm in the morning, this is the expected pharmacological response, not a warning. Document it, inform your cardiologist at your next visit, and continue monitoring weekly using your wearable device. (Masson et al., Cardiovascular Diabetology, 2019)

Cardiologist's calibrated position, Solid (1) for the 2–4 bpm expected increase. Promising (2) for the reassurance that this increase is not associated with worse outcomes in the SELECT population.

What to do: Track your resting heart rate weekly, not daily. What matters is whether the increase stabilizes or continues climbing. An increase that plateaus at 5–6 bpm above baseline after six weeks is the expected pattern. An increase that continues rising after eight weeks warrants a physician check-in.

For the full picture, read The Drug That Surprised Cardiologists.